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Abstract
Background: Human microsatellite-stable (MSS) colorectal cancers (CRCs) are immunologically “cold” tumour
subtypes characterized by reduced immune cytotoxicity. The molecular linkages between immune-resistance and
human MSS CRC is not clear.
Methods: We used transcriptome profiling, in silico analysis, immunohistochemistry, western blot, RT-qPCR and
immunofluorescence staining to characterize novel CRC immune biomarkers. The effects of selective antagonists
were tested by in vitro assays of long term viability and analysis of kinase active forms using anti-phospho antibodies.
Results: We identified the lymphocyte antigen 6 complex, locus G6D (LY6G6D) as significantly overexpressed (around
15-fold) in CRC when compared with its relatively low expression in other human solid tumours. LY6G6D up-regulation
was predominant in MSS CRCs characterized by an enrichment of immune suppressive regulatory T-cells and a limited
repertoire of PD-1/PD-L1 immune checkpoint receptors. Coexpression of LY6G6D and CD15 increases the risk of
metastatic relapse in response to therapy. Both JAK-STAT5 and RAS-MEK-ERK cascades act in concert as key regulators
of LY6G6D and Fucosyltransferase 4 (FUT4), which direct CD15-mediated immune-resistance. Momelotinib, an inhibitor
of JAK1/JAK2, consistently abrogated the STAT5/LY6G6D axis in vitro, sensitizing MSS cancer cells with an intact JAK-
STAT signaling, to efficiently respond to trametinib, a MEK inhibitor used in clinical setting. Notably, colon cancer cells
can evade JAK2/JAK1-targeted therapy by a reversible shift of the RAS-MEK-ERK pathway activity, which explains the
treatment failure of JAK1/2 inhibitors in refractory CRC.
Conclusions: Combined targeting of STAT5 and MAPK pathways has superior therapeutic effects on immune resistance.
In addition, the new identified LY6G6D antigen is a promising molecular target for human MSS CRC.
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Background
Colorectal cancer (CRC) development involves complex
interactions between malignant cells and immune system,
not comprehensively defined [1]. Targeted therapies have
improved patient outcomes. However, multiple drug resist-
ance mechanisms often converge to reactivate the original
pathway targeted by these drugs or alternatively compensa-
tory kinase cascades [2]. Mutations in Mitogen-activated
protein kinase (MAPK) cascade, phosphoinositide 3-kinase
CA (PIK3CA) or aberrant activation of tyrosine kinase re-
ceptors (HER3 or MET) function as prominent factors of
resistance [3, 4].
In CRC patients, only a modest clinical effect of MAPK
inhibitors has been reported. In this context, studies have
shown that CD15, also called Lewisx antigen, synthetized
by Fucosyltransferase 4 (FUT4), is induced by the RAF-
MEK-ERK signaling pathway, and colon cancers that are
FUT4+/CD15+ seem to exhibit significant alteration of
the systemic immune surveillance and resistance to the
anti-EGFR agents (cetuximab) [5]. This mechanism blocks
cytotoxic T lymphocyte activities against tumour cells,
making malignant cells progressively more aggressive and
difficult to treat [6, 7]. It is well known that microsatellite
instability (MSI) and mismatch repair (MMR) defects can
lead to DNA hypermutation and the production of im-
munogenic neo-peptides, recognized by antigen-specific
tumour infiltrating lymphocytes, which is counterbalanced
by the upregulation of multiple immune checkpoint mole-
cules [8–10]. These tumours are characterized by a pre-
dominant type of T helper cells (Th) with Th1 phenotype
(Th1), which potentiate the lytic function of cytotoxic
effector T cells present in the tumor microenvironment,
activating IFNγ, IL-15 and JAK (Janus kinase)/STAT (sig-
nal transducer and activator of transcription) pathways
[11, 12]. Tumours defective in MMR machinery represent
only 5% of all metastatic colorectal cancers and they are
more easily recognized by the immune system [13].
The Food and Drug Administration (FDA) has recently
approved the checkpoint inhibitor anti-Programmed cell
death protein 1 (PD1) for the treatment of metastatic
MMR defective CRC, when the disease has progressed
after chemotherapy [13]. Unfortunately, mutations in
(JAK1/JAK2) or class I MHC molecules (TAP2, B2M) and
other still unknown signaling molecules can promote an
inadequate immune response against tumours [14, 15]. In
addition, the identity of tumour-intrinsic immune antigens
that interfere with cancer immunogenicity and antitumour
T cell responses in MMR proficient tumours are poorly
understood. The lymphocyte antigen 6 complex, locus
G6D (LY6G6D) belongs to a cluster of leukocyte antigens
located in the major histocompatibility complex (MHC)
class III region on chromosome 6 [16]. LY6G is a small
protein attached to the cell surface by a glycosylphosphati-
dylinositol (GPI) anchor, employed as a marker to identify
granulocytes and myeloid-derived suppressor cell sub-
populations in mouse [16]. LY6G family members
might be useful as cancer vaccines and drug conjugated
antibodies, but their relevance in human diseases re-
mains enigmatic [16–18].
We here used in silico approaches, expression profiling
and in vitro functional assays to characterize novel cancer-
specific immune antigens in poorly immunogenic colon
cancer subtypes. Our data identify LY6G6D antigen as a
potential molecular target for human microsatellite stable
tumours and provide evidences supporting that a combined
targeting of MAPK and STAT5 signaling can improve the
therapeutic response in this subtype.
Methods
Materials and Methods and any associated references
are described more in detail within the Additional file 1.
Gene expression data analysis among different tumor
subtypes
The Gene Expression Profile from 604 cancer cell lines
representative of 14 different tumor sites from the Cancer
Cell Lines Encyclopedia series were analyzed. We selected
a collection of ~ 6000 known human genes with immuno-
modulatory functions from InnateDB, Innate Immunity
Genes curated database (http://allergen.innatedb.com/).
ANOVA analysis was adopted to test for differential expres-
sion among different tumor subtypes while eta squared was
used to determine those with a greater effect size. A series
of 55 colorectal cancer cell lines from the Cancer Cell Lines
Encyclopedia was selected to visualize DNA copy number
and mutational load. A total of 17 cancer types were re-
trieved from The Cancer Genome Atlas (TCGA) dataset to
analyze gene expression levels.
Immune cell type enrichment analysis
To analyze the expression changes related to specific im-
mune cell subpopulations, we applied a deconvolution ap-
proach based on Gene Set Enrichment Analysis (GSEA).
Unsupervised hierarchical clustering was then applied on
the Euclidean distance and Ward linkage method on the
matrix of the enrichment scores.
Patient samples and tissue microarrays analysis
Two independent datasets of patients with sporadic CRC
were retrospectively recruited and collected (Additional
file 2: Table S1 and Table S2). Additional samples included
sections of fresh tissue specimens from tumor and
matched normal adjacent mucosa frozen in liquid nitro-
gen. The recruitment of the patients was performed in ac-
cordance with the ethical guidelines, protocol number:
1703/2016 of September 2016 from the San Filippo Neri
Hospital, Rome, Italy. The tissue microarrays (TMAs)
used for this study included tumor tissue from 516
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unselected colon carcinoma and 92 corresponding normal
mucosa specimens. Construction of the TMAs has been
previously described [5].
Immune localization and western blot analysis
TMA slides were stained individually with horseradish
peroxidase-conjugated avidin biotin complex (ABC) as
previously reported [5]. Infiltrating immune cells were
counted automatically by using ImageJ-based software.
Whole tissue sections were used for double immuno-
fluorescence analysis.
Cell lines, drugs and proliferation assay
Human colon cancer cell lines were purchased from
American Type Culture Collection (ATCC, Rockville, MD,
USA) or kindly donated from other laboratories and they
were cultured as described [5]. All cell lines were myco-
plasma free. Each drug was diluted in culture medium, just
before each experiment. The data from the Genomics of
Drug Sensitivity in Cancer project (Sanger panel) were re-
trieved for more of 30 colon cancer cell lines. A set of 481
small-molecules that collectively modulate a broad array of
cell processes (https://portals.broadinstitute.org/ctrp/) was
used to identify colon cancer dependencies to inhibitor
molecules. Cell proliferation/survival was measured using
the 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium
bromide (MTT). The IC50 was determined by interpolation
from the dose response curves. Long term viability fol-
lowing drug treatments was assessed by colony forma-
tion assays.
Analysis of Kinases active forms, RNA interference and
quantification of mRNA by RT-qPCR
The analysis of Kinases in its active form was performed
by using specific antiphospho antibodies that recognized
the phosphorylated active forms normalizing with to
antibodies against the total protein. For RNA interfer-
ence, small inhibitor specific RNAs and scrambled con-
trol were transiently transfected into cells. Reverse
Transcription Real-Time Quantitative PCR (RT-qPCR)
was used to quantitatively determine mRNA expression
normalized to GAPDH mRNA or rRNA 18S levels.
Statistical analysis
The statistical analyses were carried out using Prism ver-
sion 4.02 (GraphPad Software, Inc), GeneSpring R/bio-
conductor v.12.5 and R based package.
Results
Upregulation of LY6G6D antigen in colorectal cancer
We initially analyzed public transcriptome microarrays
data derived from 604 human cancer cell lines [19] rep-
resentative of 13 solid tumours to identify differentially
expressed immune-related genes derived from Immport
collection (http://www.immport.org/immport-open/pub-
lic/home/home, (Fig. 1a). Gene expression profile using
unsupervised hierarchical cluster analysis showed that
eight genes clustered in a single branch were enriched in
colon cancer as compared to other cancers (FDR < 0.01;
eta squared > 0.3) (Fig. 1a and Additional file 3: Figure S1a).
Notably, two genes of cluster i) a member of the lympho-
cyte antigen-6 (Ly6) complex, locus G6D (LY6G6D), local-
ized on the MHC class III region (6p21) and ii) a member
of the fucosyltransferase genes (FUT4), encoding for the
fucosylated Lewisx antigen, here called CD15, as reported
[5], were highly overexpressed in CRC, discriminating MSI
and MSS subtypes (Fig. 1a, Additional file 3: Figure S1a).
To test the robustness of these predictions, we analyzed
primary CRC samples from three independent datasets,
TCGA, GSE20916 [20] and GSE41258 [21] using as a
control matched normal colonic tissues. In all data sets,
LY6G6D was highly expressed in colorectal cancer com-
pared to normal tissues, whereas FUT4 expression levels,
tended to be significantly higher in CRC than in normal
mucosa in two out of three databases (Fig. 1b). For the
remaining genes of the cluster, their expression levels were
lower or unchanged in CRC, compared to normal mucosa
(Additional file 3: Figure S1b).
As LY6G6D and FUT4 tended to be upregulated in
MSS (typically poorly immunogenic), but not in MSI
(typically highly immunogenic) CRC cell lines, we then
analyzed other primary tumours by using GSE13294 [22]
and GSE30540 [23] datasets, where MS status and chromo-
somal instability were available. Notably, we confirmed that
LY6G6D expression levels were significantly higher in MSS
than in MSI subset and tend to be significantly higher in
chromosomal instability high (CIN-high) than in CIN-low
tumours (Fig. 1c). In addition, analysis of additional datasets
(n = 569) revealed that primary CRC surgical specimens
can be discriminated in low or high-LY6G6D, but not on
the basis of FUT4 expression levels (Additional file 3:
Figure S1c).
Ly6G6D and FUT4 characterize distinct immunophenotypes
in colorectal cancer
To unveil signaling pathways regulating LY6G6D and
FUT4, we carried out a network analysis to look for
potential interactions and regulators. We found that pro-
tein kinases, mainly MAPKs (ERKs and p38 MAPKs)
and STAT5 regulated FUT4 and LY6G6D expression,
respectively (Fig. 1d). To establish the relevance of these
findings, we determined the expression of genes from
MAPKs and JAK/STAT cascades in distinct CRC sub-
types (TCGA, n = 276) stratified as MMR status. While
components of MAPK cascades were broadly expressed,
the majority of JAK/STAT genes presented higher ex-
pression in MSI than in MSS tumours according with
literature [13]. Notably, among JAK/STAT genes, only
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STAT5 showed higher expression in MSS than in MSI
and clustered with MAPK genes (Fig. 1d). Indeed, a
review of exome sequencing data (N = 2078 CRCs
from cbioportal) showed a high prevalence of JAK1/2
mutations, but not of STAT5, in hypermutated tu-
mours [10, 14] (Additional file 3: Figure S2a).
As ERKs and JAK/STAT5 cascades have been implicated
in immune evasion, we analyzed tumor-infiltrating im-
mune cell subpopulations in relation to gene expression
levels of LY6G6D, FUT4 and others key immune modula-
tory molecules. Immune cell deconvolution revealed that
CRCs clustered based on enrichment of distinct immune
cell types (Fig. 2a and b and Additional file 3: Figure S2b).
In particular, we found that a CRC subtype characterized
by high Tregs and low dendritic cells (DC) showed high ex-
pression levels of LY6G6D in concurrence with decreased
expression levels of several immune checkpoint molecules
such as CTLA-4 and PD1 [2, 3] (Fig. 2a and b Cluster 2,
green). Similar observations were obtained using an inde-
pendent dataset of validation. Also in this case, high levels
of LY6G6D expression were correlated with high infiltrates
of immune suppressive cell types, such as the regula-
tory T cells (Tregs) and T helper 2 (Th2) cells, which
play a key role as mediators of antitumor immunity
(Additional file 3: Figure S2c, Cluster 4, green). On the
contrary, FUT4 tended to be upregulated in malignant
a
c
d
b
***
*** *** **
*
*
Fig. 1 Characterization of LY6G6D and FUT4/CD15 expression. a The work flow on the left shows cancer cell line transcriptomic samples that
were retrieved from NCBI (Barretina J et al. 2102) and interrogated for differentially expressed genes of known immune-related genes from
ImmPort collection. Right, unsupervised hierarchical cluster of cancer cell lines (n = 604) shows a gene signature enriched in colorectal cancer.
Enlarged image shows two genes LY6G6D and FUT4/CD15 within the cluster that are upregulated in Microsatellite stable (MSS) but not in
microsatellite instable (MSI) colon cancer cells categorized for mutational load and copy number variations (CNVs). b Quantification of CD15 and
LY6G6D mRNA in patient-matched tumor-normal mucosa extracted from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO)
data sets. Scatter plot in which each circle represents mRNA levels in each tumor sample, horizontal line is the mean value. *P ≤ 0.05; **P ≤ 0.01;
***P ≤ 0.001 by Mann–Whitney U test. c Heat map of log-transformed odds ratios of a set of immune-related genes for two different molecular
phenotypes MSI vs MSS. On the left, quantification of LY6G6D mRNA by a box plot in CRCs classified as CIN high or low based on a weighted
genome integrity index (see Methods). *P≤ 0.05; t test Welch-corrected. d Enrichment map network of statistically significant gene interactions.
Nodes represent gene hub and lines their connectivity. Node size is proportional to number of line with arrows. Heat map of differentially
expressed genes within JAK/STAT and MAPK signaling according to MSI-H, MSI-L, MSS subtypes. Shown are groups with high relative expression
(hi, red) versus the low relative expression (lo, blue) at the optimum value cutoff
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cells (Fig. 2c) displaying no significant correlation with
specific immune cells type, consistent with literature [5].
These observations suggest that LY6G6D and FUT4 may
be responsible for cancer progression acting as tumour-
intrinsic immune suppressive factors.
Coexpression of LY6G6D and CD15 promotes cancer
progression in concert
To further investigate the role of LY6G6D and FUT4, we
focused on CD15, a cell-surface antigen encoded by FUT4,
whose over-expression in metastatic CRC is associated with
Fig. 2 Intra-tumoral immunophenotypes marked by LY6G6D and FUT4/CD15. a On the top, unsupervised hierarchical cluster of 232 CRC
samples (dataset: GSE17536–37) using cell-specific immune-signatures categorized patients into four groups, with distinct cell immune
associated gene expression. Data are obtained using the Euclidean distance and Ward linkage method on the matrix of the enrichment
scores calculated through ssGSEA. Top tracks represents the expression profile of known immune inhibitory molecules, together with
LY6G6D and CD15/FUT4 genes. On the bottom, boxplots of LY6G6D gene expression in each cluster. b Dot plot representing the mean
enrichment scores of each immune cell type in any cluster. Color scale represents the positive (red) and negative (blue) enrichment
score; dot size indicates the strength of the association. c representative western blot images and quantification of LY6G6D and CD15
expression from CRC samples and matched normal mucosa (n = 12) relative to β-actin used as loading. Data are mean ± standard error of
the mean (s.e.m); (n = 3 biological replicates, P* < 0.05, ***P < 0.001, two-tailed Student’s t-test. Low, LY6G6D and CD15 IHC in normal
mucosae and tumor specimens; Scale bar, 100 μm. Enlarged is the staining in both malignant cells (T) and stromal (S) immune cells.
d Correlation between LY6G6D+ cells, CD8 T-lymphocytes and CD86 staining in CRC samples (five replicates counts, cells mm− 2). Double
immunofluorescence from paraffin embedded sections co-stained with antibodies against CD4 (red) and FOXP3 (red) or LY6G6D (green).
Scale bar, 50 μm and 20 μm, respectively
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lack of response to EGFR and VEGF inhibitors [5]. We
studied by western blot analysis our in-house snap frozen
CRCs (n = 12) and healthy mucosa samples (n = 12) ob-
tained from the same patient. We observed increased
expression of LY6G6D and CD15 in primary CRC as
compared with healthy mucosa. Semi-quantitative pro-
tein analysis revealed that LY6G6D, but not CD15, was
consistently higher in stages III and IV than in stages I
and II of primary tumours (Fig. 2c).
Next, we performed immunohistochemistry (IHC) in
two independent datasets (I and II) comprising 517 sur-
gically resected tumors and 77 normal mucosa samples
(Additional file 2: Tables 1 and 2). IHC results revealed that
approximately 70% of tumours expressed CD15 in ma-
lignant cells (Additional file 3: Figure S3a), which corre-
lated with a reduction in the infiltrating neutrophils
and monocytes (Fig. 2c), in line with previous findings
[5]. Notably, more than 80% of tumours exhibited
LY6G6D staining, compared to 20% of normal tissues
(Additional file 3: Figure S3a). Accordingly, double
immunofluorescence on paraffin embedded tumours
revealed that CD4+ and FOXP3+ T cells (Treg) were
positive for LY6G6D staining, whereas CD8+ T lym-
phocytes did not (Fig. 2d and Additional file 3: Figure
S3b).
The number of infiltrating LY6G6D positive cells was
significantly higher in CRC than in normal mucosa. In
fact, tumours with increased number of infiltrating leu-
cocytes exhibited stronger LY6G6D expression in malig-
nant cells (Fig. 2c and 3a).
We next explored the nature of immune tumor micro-
environment in MSI and MSS tumours by immunohis-
tochemistry. We found that intratumoral staining of
LY6G6D in both malignant and infiltrating immune cells
was higher in MSS than MSI tumors (Fig. 3b and c). In
contrast, MSI subset exhibited stronger PD1 and PD-L1
staining as compared to MSS tumours (Fig. 3b and c).
Accordingly, JAK1 staining revealed the presence of
higher levels of JAK1 in MSI than in MSS. Moreover,
tumours positive for JAK1, PD1 and PDL1 were associated
a b
c d
Fig. 3 Immune inhibitory molecules in MSI and MSS tumours. a quantification of infiltrating LY6G6D positive cells expressed as mean of five
replicates counts, cells mm− 2) in normal mucosa and CRC samples. Correlation between LY6G6D+ cells, p-STAT5 staining in CRC samples (five
replicates counts, cells mm− 2). b Examples of MSI and MSS CRC stained by immunohistochemistry against MLH1, LY6G6D, PDL1 and PD1. T,
Tumour, S, stromal compartment. Scale bar, 50 μm. c Quantification of stromal infiltration and staining of malignant cells by immunohistochemistry for
LY6G6D, PDL1 and PD1. P* < 0.05, P** < 0.01, ***P < 0.001, by the Chi-squared test. d Kaplan–Meier curve showing the time to disease progression in
relation to LY6G6D and CD15 status (n = 187); The p-value by log-rank test. Response to treatment according to LY6G6D IHC in primary metastatic
tumors (n = 83) subdivided for complete (CR); partial (PR) responses; stable disease (SD) and progression disease (PD); P* < 0.05, P** < 0.01, ***P < 0.001,
by the Chi-squared test
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to a favorable prognosis as compared to those negative ones
(Additional file 3: Figure S4a-d). Notably, phospho-Stat5
(P-STAT5) and LY6G6D positive staining displayed a direct
correlation, so that, tumours with high levels of P-STAT5
and LY6G6D (LY6G6Dhi) were associated with a shorter
patients survival rate (Fig. 3a and Additional file 3:
Figure S3d and Figure S4a-d).
Consistent with these results, the screening of dataset II
alone confirmed that LY6G6Dhi tumours correlated with
shorter disease-free survival and a reduced response to
therapy compared to LY6G6D-low/neg tumours (Fig. 3d and
Additional file 3: Figure S4d). In this latter database, coex-
pression of LY6G6Dhi/CD15hi resulted in a poorer clinical
outcome compared to each marker alone. We observed
that the relapse-free survival at 5 years was only 33,6% for
LY6G6Dhi/CD15hi patients compared to more than 95% for
CD15neg/LY6G6Dneg subgroup. Intermediate results were
obtained for the remaining group of patients (Fig. 3d).
These results suggested that elevated levels of LY6G6D and
CD15 may promote disease progression by inducing im-
mune subversion of the tumor microenvironment.
JAK/STAT and MEK inhibitors potently suppress the
growth of poorly immunogenic CRC cells
To understand how ERKs and JAK/STAT5 signaling regu-
lates CD15/FUT4 and LY6G6D function, we first investi-
gated the treatment response of human CRC cells (N = 38)
to the MEK inhibitor, Trametinib, and the JAK1/2 inhibi-
tor, ruxolitinib, by integrating genomic and transcriptomic
data from the Cancer Cell Line Encyclopedia (CCLE) and
Genomics of Drug Sensitivity from Cancer project,
https://www.cancerrxgene.org/ (Fig. 4a and b). This
a b
c d
Fig. 4 Response to JAK/STAT and MEK inhibitors in CRC molecular subtypes. a Heat map showing mutation/expression of JAK/STAT genes in
relation to mutation load, LY6G6D and CD15/FUT4 expression in CRC cancer cell lines (n = 38). b A chemo-immune-sensitizer approach targeting
LY6G6D and CD15/FUT4 by JAK/STAT and MEK inhibitors. Right, Log10 IC50 values for treatment of MSI and MSS CRC cell lines with ruxolitinib
(JAK/STATi) and trametinib (MEKi) extracted from the Genomics of Drug Sensitivity in Cancer project. c RKO (MSI-H) and SW620 (MSS) stained
with LY6G6D (green) and CD15 (red). Bottom right, basal activation of stat1, stat3, stat5 in a panel of CRC cell lines. Down left, western blotting
showing expression of P-STAT5, STAT5 P-ERK1/2, ERK1/2 and LY6G6D. Down right, quantification of P-STAT5, P-ERK1/2 and LY6G6D relative to β-
actin. d Cells were treated with different concentrations of momelotinib (range, 1 nM to 1mM for 96 h) and evaluated for proliferation by MTT
staining. Right, boxplot of log10 IC50 values for treatment of five CRC cell lines (RKO,HT29, SW480, SW620, HCT116) with ruxolitinib vs
momelotinib. Results are representative of three biological replicates. P-value by two-tailed Student’s. P* < 0.05, **P < 0.01
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screening revealed that in poorly immunogenic cells
(MSS), characterized by the lack of JAK–STAT muta-
tions, CD15/FUT4 and LY6G6D upregulation have a
low sensitivity to the JAK inhibitor. In contrast, the
treatment with trametinib was highly effective in this
subset of tumours (Fig. 4a and b).
To corroborate these findings, we employed in-house
CRC cell lines (RKO, HCT116, HT29, SW620, SW480) to
analyze CD15/FUT4 and LY6G6D expression. According
with previous data, CD15 was predominantly localized in the
plasma membrane, while LY6G6D formed aggregates-like
structure into the cytosol that were more abundant in MSS
than in MSI cells (Fig. 4c). Notably, we found that ERKs and
STAT5 activation under basal conditions were inversely cor-
related. The highest levels of P-STAT5 were detected in
metastatic cell lines (i.e. SW620), which were characterized
by enhanced LY6G6D protein expression (Fig. 4c).
To further characterize which JAK/STAT inhibitor po-
tentially interfered with LY6G6D, we treated colon cancer
cells with ruxolitinib or momelotinib (Mom) alone. Not-
ably, CRC cell lines were significantly more sensitive to
momelotinib than ruxolitinib (around 30-fold) (Fig. 4d and
Additional file 3: Figure S5a). A screening from the cancer
therapeutics response portal (https://portals.broadinstitu-
te.org/ctrp/) to find molecule drugs that target the JAK/
STAT cascade more selectively, confirmed that momemoli-
tib was one of the most effective molecules to inhibit
STAT5 signaling (Additional file 3: Figure S5b). In line with
this, STAT5b copy number variations was directly cor-
related with the sensitivity to momemolitib in a panel
of colon cancer cells (N = 34; pearson correlation 0.308,
Additional file 3: Figure S5b). These results indicated
that momelotinib could be a good candidate to inhibit
STAT5/LY6G6D axis, supporting further investigation
about its effects when used in combination with the
MEK inhibitor.
Indeed, we found that the treatment with momelotinib
or trametinib and its combination (JAKi/MEKi) resulted
in a dramatic suppression of the growth rate of CRC
cells known to have a primary resistance to Mab cetuximab
(anti-EGFR) [24] (Additional file 3: Figure S5c and d). Con-
sistent with these results, we extended the pharmacological
treatment to a largest panel of cells analyzing colony forma-
tion. Interestingly, the JAK1/2 inhibitor enhanced the
growth inhibitory effect of the MEK-inhibitor, particularly
in poorly immunogenic BRAF or KRAS mutant cancer cells
(HT29 and SW620) (Fig. 5a). In contrast, more immuno-
genic cancer cells with endogenous JAK2 deletion and
BRAF or KRAS mutation (RKO and HCT116) displayed
tolerance to momelotinib, reducing the combinatory effect
(Fig. 5b). Taken together, these results indicate that tu-
mours bearing LY6G6D and CD15 might be targeted by
this treatment strategy, particularly those from MSS CRC
subgroup.
The JAK/STAT inhibitor, momelotinib, increases cell-death
through targeting STAT5/LY6G6D axis
To understand whether the treatment with momelotinib
affected the STAT5-mediated LY6G6D upregulation, we
used as a metastatic model, the SW620 cell line, which
is characterized by endogenous STAT5 activation and
increased LY6G6D expression. We observed that mome-
lotinib vigorously inhibited both STAT5 activation and
endogenous LY6G6D expression (Fig. 5c). According with
this datum, transient STAT5 silencing markedly reduced
LY6G6D levels, indicating that both pharmacologic and
genetic blockade of STAT5 signaling results in LY6G6D
downregulation (Additional file 3: Figure S6a).
Notably, momelotinib induced a robust dose-dependent
activation of ERKs signaling in a heterogeneous panel of
cancer cells regardless of (HER3) activation (Fig. 5c and
Additional file 3: Figure S6a,b). A similar effect on ERKs
activation was observed upon exposure to ruxolitinib,
supporting the hypothesis that colon cancer cells became
sensitized to JAK inhibitors when they are treated with
inhibitors of MEK-ERK pathway [25] (Additional file 3:
Figure S6b). The treatment with trametinib did not alter
LY6G6D expression, while confirmed FUT4/CD15 as a key
mediator of RAF-MEK-ERK pathway [5] (Fig. 5c and
Additional file 3: Figure S6c). Analysis of different MEKi
using the public database, GDS5029 [24], supported that
STAT5/LY6G6D signaling is a downstream mediator of
resistance to MEKi in KRAS mutant CRCs (Additional
file 1: Figure S6d). In addition, blocking the RAF-MEK-
ERK cascade by trametinib, we found an increased
phosphorylation of STAT3, another member of the Stat
family (Additional file 3: Figure S6c).
Given that KRAS or JAK1/2 mutations interfere with
the IFN/STAT signaling pathway [26, 27], it was tested the
sensitivity to the MEK/JAKi treatment in HCT116 cell line
(bearing mutant K-Ras) and its derivative HKE-3 with wild
type KRAS (wtK-Ras). We observed that the cell line ex-
pressing wtK-Ras displayed a lower viability in response to
the drug combination than the cell line expressing mutant
K-Ras (Fig. 5c). Remarkably, the combined treatment sig-
nificantly abrogated LY6G6D and CD15/FUT4 expression
in the cell line expressing wtK-Ras, but not in that with
mutant KRAS (HCT116) (Additional file 3: Figure S6d).
Therefore, these results indicate that upregulation of
LY6G6D and CD15/FUT4 can be efficiently abolished
using a combination of JAK/STAT and MEK inhibitors in
poorly immunogenic CRC subset.
Discussion
It has been hypothesized that genetic alterations affecting
signaling pathways can produce malignant variants resistant
to immune effectors. We here provide evidence that
LY6G6D is an antigen activated through JAK/STAT5
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pathway in poorly immunogenic CRCs. Our hypothesis is
also consistent with previous studies where systemic
Ly6G+ cell depletion suppresses colitis-associated tumori-
genesis and ApcMin/+ adenoma formation through
CXCR2-dependent tumor-associated leukocytes [28].
Therefore, LY6G6D might also act as a critical mediator
of malignant growth and immune evasion in human CRC.
We have confirmed LY6G6G expression in both cancer
cells and Regulatory T cells (Treg), which are a highly
immune-suppressive subset of T cells that prevents the
development of effective antitumor immunity [29].
Genomic data from the TCGA database are in agreement
with our observations that both Tregs and myeloid-
derived suppressor cells (MDSCs), are enriched in
non-hypermutated tumors but not in MSI CRCs [9, 12,
13]. Consistent with this, LY6G6D expression is also en-
hanced in rare immune diseases, such as the autosomic
dominant monocytopenia, characterized by systemic im-
mune suppression.
Notably, STAT5 activation is also required for the
expansion of Treg or induction of specific immune
checkpoint molecules [30, 31]. Ly6 genes may inhibit the
formation of membrane attack complexes in tumor cells
hampering cytolytic activity of T cells. However, the
identity of their interacting partners remains a mystery
[16]. Our observations reveal that MMR proficient can-
cers characterized by less CD8+ T lymphocytes and low
expression of PD-1/PD-L1 exhibit enhanced LY6G6D
Fig. 5 MSS CRC cell lines are highly sensitive to STAT5/MEK inhibitors. a MSS BRAF(V600E), KRAS mutant and b MSI BRAF(V600E), KRAS mutant
CRC cells were seeded at low confluence and treated with increasing concentrations (lower than IC50 values) of momelotinib, trametinib or in
combination (comb) twice a week. Viability was assessed by a colony formation assay. Cells were fixed, stained, and photographed after 10 days
of culture. For each cell line, in the low panel the percent of cell growth inhibition determined by treatment is shown. Results represent three
separate experiments, each performed in triplicate. P-value by two-tailed Student’s (related to untreated vehicle control) are shown, P* < 0.05,
**P < 0.01, ***P < 0.001, NS, non significant. c representative immunoblot of phosphorylated STAT5 and ERK1/2 compared to LY6G6D following
treatment with momelotinib, trametinib or combination. Bottom right, quantification to β-actin. Low left, viability of HCT116 cell lines (KRAS
mutant), and its derivative HKE-3 KRAS wild type (KRASWT) to momelotinib, trametinib or their combination assessed by colony formation assay.
Low on the right, quantification of LY6G6D and FUT4 mRNA by RT-PCR analysis following drug treatments. ***P < 0.001 by Mann–Whitney U test.
d Illustration of immune suppressive pathway mediated by LY6G6D and CD15, which could predict response to JAK- and MAPK-directed
therapies in microsatellite stable CRC
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expression and STAT5 activation, implicating Ly6 genes
as novel candidates for the development of new targeted
therapies [17, 18] (Fig. 5d).
The functional activity of JAK/Stat5 pathway can be
regulated by the ERKs signaling, which controls the
transcriptional upregulation of FUT4, resulting in an
increased cell-surface expression of CD15 and resistance
to the anti-EGFR agents [5, 32]. In line with this, coex-
pression of LY6G6D and CD15 increases the risk of dis-
ease progression in response to therapy, suggesting that
both MAPK and Stat5 pathways likely foster colon can-
cer progression in concert.
Although dysregulated JAK–STAT signaling represents
an attractive therapeutic target for modulating the immune
responses [33], JAKs inhibitors have shown limited clinical
utility in solid tumours, including patients with refractory
colorectal adenocarcinoma [34, 35]. A potential mechanism
would be that mutations in JAK1/JAK2 might block PD-L1
induction, protecting cancer cells from immune attack [34].
Not unexpectedly, we found that CRC cell lines mutant for
JAK2 were less sensitive to the JAK/STAT inhibitor, mome-
lotinib. Conversely, LY6G6D positive MSS cells (SW620)
suppress T cell proliferation through the expansion of
myeloid-derived suppressor cells, which were more vulner-
able to momelotinib [36]. In this context, a recent study
suggests that momelotinib reduces the number of cancer
stem cells associated to tumor burden in a mouse model of
human ovarian cancer [37]. However, in CRC cancer cell
lines aberrant activation of MAPK signaling (RAS mutation
or ERKs activation) was consistently involved in the mech-
anism of resistance to momelotinib.
Ruxolitinib, the first JAK/STAT inhibitor approved by
the FDA, enhances the expression of angiogenic factors
by inducing NK cell–mediated tumor progression, suggest-
ing that combined targeting of JAK/STAT and VEGF sig-
naling can improve therapeutic response [34]. This idea is
supported by our observation that combined analyses of
CD15 and LY6G6D should be evaluated as predictive bio-
markers for the response to JAK- and MAPK-directed ther-
apies. The anti-Ly6G antibody has been routinely used to
deplete Ly6G+ cells in mice models, and it is well-tolerated
and effective in a long term treatment. Its use might be an
additional promising strategy to confer susceptibility to
therapies in non-immunogenic and refractory human CRC.
However, the treatment effects in human patients with
colorectal cancer may significantly differ. Therefore, further
investigation will be required to fully elucidate the mechan-
ism by which LY6G6D promotes cancer progression.
Conclusions
We here provide evidence that LY6G6D and CD15 pro-
mote chemo-immune-resistance in immunologically com-
promised colon cancers and can be used as biomarkers to
decide patients treatment. Further preclinical studies would
reveal if LY6G6D and CD15 antagonists, in addition to
established chemotherapeutic protocols, can improve ther-
apy response in refractory colorectal cancer.
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